Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques
- PMID: 15589853
- DOI: 10.1016/j.fertnstert.2004.06.041
Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques
Abstract
Objective: To investigate the role of exogenous LH in controlled ovarian hyperstimulation for assisted reproductive technologies.
Design: Prospective randomized study.
Setting: SISMER fertility unit.
Patient(s): Women showing a hyporesponsiveness to FSH under GnRH agonist down-regulation were randomized into three groups: group A (n = 54) received an increased dosage of FSH; group B (n = 54) was administered recombinant LH in addition to the increased dose of FSH; group C (n = 22) was given additional FSH and LH using hMG as a combined drug. Fifty-four age-matched women with no need to increase the FSH dose were included as a control group (D).
Intervention(s): None.
Main outcome measure(s): Implantation and live birth rate per started cycles.
Result(s): In group B, the pregnancy and implantation rates were statistically higher when compared with groups A and C and did not differ from the control group for normal response. The live birth rate was similar in groups B and D but was half as high in groups A and C.
Conclusion(s): Hyporesponsiveness to FSH could be related to iatrogenic LH deficiency that, in turn, could affect oocyte competence. Addition of a small amount of recombinant LH is able to rescue oocyte competence to produce viable embryos.
Comment in
-
Optimal study design and the CONSORT guidelines.Fertil Steril. 2005 Oct;84(4):1057-8; author reply 1058. doi: 10.1016/j.fertnstert.2005.06.009. Fertil Steril. 2005. PMID: 16213877 No abstract available.
Similar articles
-
Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders.Fertil Steril. 2007 Sep;88(3):665-9. doi: 10.1016/j.fertnstert.2006.11.150. Epub 2007 Feb 12. Fertil Steril. 2007. PMID: 17292895 Clinical Trial.
-
Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.Fertil Steril. 2008 Mar;89(3):546-53. doi: 10.1016/j.fertnstert.2007.03.088. Epub 2007 May 29. Fertil Steril. 2008. PMID: 17531989 Clinical Trial.
-
A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.Fertil Steril. 2006 Jul;86(1):58-63. doi: 10.1016/j.fertnstert.2005.12.040. Epub 2006 Jun 6. Fertil Steril. 2006. PMID: 16753156 Clinical Trial.
-
The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis.Fertil Steril. 2012 May;97(5):1108-14.e1. doi: 10.1016/j.fertnstert.2012.01.130. Epub 2012 Feb 24. Fertil Steril. 2012. PMID: 22365075 Review.
-
Does exogenous LH in ovarian stimulation improve assisted reproduction success? An appraisal of the literature.Reprod Biomed Online. 2012 Mar;24(3):261-71. doi: 10.1016/j.rbmo.2011.12.005. Epub 2011 Dec 20. Reprod Biomed Online. 2012. PMID: 22285265 Review.
Cited by
-
Dosing Characteristics of Recombinant Human Luteinizing Hormone or Human Menopausal Gonadotrophin-Derived LH Activity in Patients Undergoing Ovarian Stimulation: A German Fertility Database Study.Gynecol Obstet Invest. 2023;88(4):214-225. doi: 10.1159/000530360. Epub 2023 Jun 27. Gynecol Obstet Invest. 2023. PMID: 37369184 Free PMC article.
-
Clinical Features and Management of Suboptimal Ovarian Response During in vitro Fertilization and Embryo Transfer: Analysis Based on a Retrospective Cohort Study.Front Endocrinol (Lausanne). 2022 Jul 22;13:938926. doi: 10.3389/fendo.2022.938926. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 37228708 Free PMC article.
-
The average gonadotrophin dosage per follicle is predictive of ovarian response and cumulative live birth chances after in vitro fertilization: a retrospective cohort study.BMC Womens Health. 2023 Feb 4;23(1):45. doi: 10.1186/s12905-023-02195-5. BMC Womens Health. 2023. PMID: 36739381 Free PMC article.
-
Effect of Exogenous Luteinizing Hormone (LH) Supplementation on Clinical Pregnancy of Patients Receiving Long-Acting Gonadotropin-Releasing Hormone Agonist (GnRHa) Cycles: A Retrospective Cohort Study.Int J Womens Health. 2022 Dec 13;14:1691-1700. doi: 10.2147/IJWH.S388726. eCollection 2022. Int J Womens Health. 2022. PMID: 36536609 Free PMC article.
-
TJZYF Improves Endometrial Receptivity through Regulating VEGF and PI3K/AKT Signaling Pathway.Biomed Res Int. 2022 Sep 23;2022:9212561. doi: 10.1155/2022/9212561. eCollection 2022. Biomed Res Int. 2022. PMID: 36193314 Free PMC article. Retracted.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
